Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348977 | 1.00 | EPHX1 (0.41) | EPHX1CA2CA1PTPN11MAPK1 | |
| SCHEMBL17435877 | 0.89 | CA1 (0.39) | EPHX1CA2CA1MAPK1SMN1; SMN2 | |
| Butane SCHEMBL30418608 | 0.82 | EPHX1 (0.50) | EPHX1CA2CA1PTPN11MAPK1 | |
| Butane SCHEMBL29598328 | 0.82 | EPHX1 (0.50) | EPHX1CA2CA1PTPN11MAPK1 | |
| SCHEMBL27093602 | 0.80 | EPHX1 (0.35) | EPHX1 | |
| Trimethylammonium SCHEMBL29395692 | 0.79 | CA2 (0.46) | EPHX1CA2CA1PTPN11MAPK1 | |
| SCHEMBL4457449 | 0.79 | CA2 (0.56) | EPHX1CA2CA1PTPN11MAPK1 | |
| SCHEMBL37874 | 0.79 | CA2 (0.56) | EPHX1CA2CA1PTPN11MAPK1 | |
| SCHEMBL22821168 | 0.77 | EPHX1 (0.38) | EPHX1CA2CA1 | |
| SCHEMBL6460339 | 0.77 | EPHX1 (0.38) | EPHX1CA2CA1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043991-B1 | HYDROFORMYLATION PROCESS USING A COBALT-BASED CATALYST IN A NONAQUEOUS IONIC LIQUID | IFP Energies Nouvelles (FR) | 2011-08-31 | — | — | EP | claimed |
| US-7781621-B2 | Hydroformylation method involving a cobalt-based catalyst in a non-aqueous ionic liquid | INSTITUT FRANCAIS DU PETROLE (FR) | 2010-08-24 | — | — | US | claimed |
| US-20100010270-A1 | HYDROFORMYLATION METHOD INVOLVING A COBALT-BASED CATATLYST IN A NON-AQUEOUS IONIC LIQUID | IFP (FR) | 2010-01-14 | — | — | US | claimed |
| US-7781621-B2 | Hydroformylation method involving a cobalt-based catalyst in a non-aqueous ionic liquid | INSTITUT FRANCAIS DU PETROLE (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20100010270-A1 | HYDROFORMYLATION METHOD INVOLVING A COBALT-BASED CATATLYST IN A NON-AQUEOUS IONIC LIQUID | IFP (FR) | 2010-01-14 | — | — | US | disclosed |
| US-20070286783-A1 | METHOD OF DEACIDIZING A GASEOUS EFFLUENT WITH EXTRACTION OF THE PRODUCTS TO BE REGENERATED | CARRETTE PIERRE-LOUIS | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010270-A1 | HYDROFORMYLATION METHOD INVOLVING A COBALT-BASED CATATLYST IN A NON-AQUEOUS IONIC LIQUID | NUDT1, GFPT1, QPCT | EPHX1 2858/4885CA2 194/4885CA1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.